A Safety and Tolerability Study of JNJ-42160443 in Patients With Moderate to Severe, Chronic Knee Pain From Osteoarthritis
- Full Text View
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to evaluate pain relief, safety, and tolerability of a new treatment (JNJ-42160443) for moderate to severe pain of osteoarthritis of the knee in comparison to a standard pain treatment and placebo.
| Condition | Intervention | Phase |
|---|---|---|
|
Osteoarthritis Osteoarthritis, Knee Pain Arthralgia Joint Pain |
Drug: Oxycodone CR (standard pain medication) Drug: JNJ-42160443 Drug: Placebo |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | A Randomized, Double-Blind, Placebo- and Active-Controlled Study to Evaluate the Efficacy, Safety and Tolerability of JNJ-42160443 as Monotherapy in Subjects With Moderate to Severe, Chronic Knee Pain From Osteoarthritis |
- Change in the average daily pain intensity [ Time Frame: From Baseline to Week 13 (ie, after 12 weeks of treatment) ] [ Designated as safety issue: No ]
- Western Ontario and McMaster Osteoarthritis Index (WOMAC 3.1) subscales scores [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]The WOMAC 3.1 is a multi-dimensional, osteoarthritis specific questionnaire designed to assess clinically important symptoms of the hip and/or knee.
- Patient Global Assessment (PGA) scale score [ Time Frame: 12 weeks ] [ Designated as safety issue: No ]The PGA is a single item that the patient completes to indicate their perception of their osteoarthritis status, on an 11-point numerical rating scale from 0 (Very Good) to 10 (Very Bad).
| Enrollment: | 196 |
| Study Start Date: | April 2010 |
| Study Completion Date: | July 2011 |
| Primary Completion Date: | July 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Experimental: JNJ-42160443 (lower dose) |
Drug: JNJ-42160443
JNJ-42160443: Type=exact number, unit=mg, number= 3, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
|
| Experimental: JNJ-42160443 (higher dose) |
Drug: JNJ-42160443
JNJ-42160443: Type=exact number, unit=mg, number= 9, form=solution for injection, route=Subcutaneous use and Placebo: Form=capsule, route=Oral use. One injection of JNJ-42160443 every 4 weeks and a placebo capsule twice a day for 16 weeks.
|
| Active Comparator: Oxycodone CR (standard pain medication) |
Drug: Oxycodone CR (standard pain medication)
Oxycodone CR: Type=exact number, unit=mg, number= 10-50, form=capsule, route=oral use and Placebo: Form=solution for injection, route=Subcutaneous use. Oxycodone CR capsule twice a day for 16 weeks and one placebo injection every 4 weeks for 16 weeks.
|
| Placebo Comparator: Placebo |
Drug: Placebo
Form=solution for injection, route=Subcutaneous use and Form=capsule, route=Oral use. One placebo injection every 4 weeks and a placebo capsule twice a day for 16 weeks.
|
Detailed Description:
This is a double-blind (neither the physician nor the patient knows the name of the assigned drug) study evaluating pain relief, safety, and tolerability of a new treatment (JNJ-42160443) for moderate to severe pain of osteoarthritis of the knee in comparison to a standard pain treatment and placebo. The study will last for about 42 weeks. Patients will receive treatment for 16 weeks. Patients who qualify for the study based on their level of pain as well as other factors will receive one of the 4 possible treatments as determined by chance. Before entering the study, patients must stop using their present pain medication. During the study, patients will answer questions about their pain, side effects, and have tests performed to monitor their physical condition. The main purpose of the study is to compare pain relief with JNJ-42160443 to that of a standard pain treatment or placebo. After the treatment period, patients can return to taking the pain medication that they used before the start of the study, and their physical condition will continue to be monitored. JNJ 42160443 10 mg/mL will be provided for use in the study. Patients will receive 1 of 4 treatments for 16 weeks (wks): lower dosage of JNJ 42160443 by subcutaneous (under the skin) (SC) injection once every 4 wks + Placebo (P) capsule orally (by mouth) (PO) 2x/day, higher dosage of JNJ 42160443 by SC injection once every 4 wks + P capsule PO 2x/day, standard pain medication capsule PO 2x/day + P by SC injection once every 4 wks, or P capsule PO 2x/day + P by SC injection once every 4 wks.
Eligibility| Ages Eligible for Study: | 40 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Clinical diagnosis of osteoarthritis of the knee
- Have moderate to severe pain based on a trial questionnaire
- Must be on a stable dose of pain medication for 4 weeks before entering the trial
- Medically stable condition
Exclusion Criteria:
- History of joint replacement surgery in the affected joint or planned surgery involving the affected joint during the trial
- Diabetes mellitus
- Uncontrolled cardiovascular disease or hypertension
- Previous treatment with another investigational NGF inhibitor therapy
Contacts and Locations
Show 42 Study Locations| Study Director: | Johnson & Johnson Pharmaceutical Research & Development, L.L. C. Clinical Trial | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
More Information
No publications provided
| Responsible Party: | Johnson & Johnson Pharmaceutical Research & Development, L.L.C. |
| ClinicalTrials.gov Identifier: | NCT01094262 History of Changes |
| Other Study ID Numbers: | CR017092, 42160443-PAI2006, 2009-016831-36 |
| Study First Received: | March 25, 2010 |
| Last Updated: | August 21, 2012 |
| Health Authority: | United States: Food and Drug Administration |
Keywords provided by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.:
|
Osteoarthritis pain of the knee Osteoarthritis Osteoarthritis, Knee Pain |
Arthralgia Joint Pain JNJ-42160443 |
Additional relevant MeSH terms:
|
Osteoarthritis Osteoarthritis, Knee Arthralgia Joint Diseases Musculoskeletal Diseases Pain Signs and Symptoms Arthritis Rheumatic Diseases Analgesics |
Oxycodone Sensory System Agents Peripheral Nervous System Agents Physiological Effects of Drugs Pharmacologic Actions Central Nervous System Agents Therapeutic Uses Narcotics Central Nervous System Depressants Analgesics, Opioid |
ClinicalTrials.gov processed this record on May 16, 2013